+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
ID07071532

Evaluating How Itraconazole Affects ABBV-932 Drug Levels and Safety in Adults with Bipolar Disorder

Led by AbbVie · Updated on 2026-09-16

20

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying how the drug ABBV-932 behaves in the body and its side effects when taken alone and together with another drug called Itraconazole in adults with bipolar disorder. The study is a Phase 1 trial focused on understanding basic science aspects of these medications in this population. Participants will first receive oral ABBV-932 alone in the first period. In the second period, they will take ABBV-932 combined with oral Itraconazole. The study aims to observe how the body processes these drugs alone and in combination. During the study, researchers will monitor participants for adverse events and measure various drug levels in the blood, including maximum concentration, time to maximum concentration, elimination rate, half-life, and area under the curve over approximately 29 days. Safety monitoring will continue for up to about 61 days. Participants will undergo medical exams, vital sign checks, lab tests, ECGs, and psychiatric assessments throughout the study.

CONDITIONS

Brief Title

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here